Novartis Manufacturing NV (batch release)

The drug is intended for the treatment of adult patients with neovascular (exudative) age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema (DME).

Dosage form: solution for injection

ATC: S01LA06